Therapeutic Impact of Gardasil<sup>®</sup> in Recurrent Respiratory Papillomatosis: A Retrospective Study on RRP Patients
<b>Background:</b> Recurrent respiratory papillomatosis (RRP) is a rare, non-malignant disease caused by human papillomavirus (HPV) types 6 and 11. The condition primarily affects the larynx, potentially leading to life-threatening airway obstruction. It is more aggressive in younger pat...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/17/3/321 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850276748919308288 |
|---|---|
| author | Jennifer Sieg Asita Fazel Elgar Susanne Quabius Astrid Dempfle Susanne Wiegand Markus Hoffmann |
| author_facet | Jennifer Sieg Asita Fazel Elgar Susanne Quabius Astrid Dempfle Susanne Wiegand Markus Hoffmann |
| author_sort | Jennifer Sieg |
| collection | DOAJ |
| description | <b>Background:</b> Recurrent respiratory papillomatosis (RRP) is a rare, non-malignant disease caused by human papillomavirus (HPV) types 6 and 11. The condition primarily affects the larynx, potentially leading to life-threatening airway obstruction. It is more aggressive in younger patients, necessitating frequent surgical interventions. This study investigates the therapeutic potential of the prophylactic HPV vaccine Gardasil<sup>®</sup> in RRP patients, focusing on its impact on lesion size and the frequency of surgical interventions. Furthermore, a literature review was conducted to analyze the factors influencing the decision to vaccinate. <b>Methods:</b> A retrospective analysis was conducted on 63 RRP patients treated from 2008 to 2021. Disease burden was assessed using the Derkay score and the annual frequency of laser-surgical ablations. Comparisons were made between pre- and post-vaccination periods in vaccinated patients (n = 18), and between first and second halves of the disease’s course in unvaccinated patients (n = 14). <b>Results:</b> A reduction in the frequency of surgical interventions post-vaccination (<i>p</i> < 0.05) could be seen. The cumulated Derkay score per year decreased after second and third vaccination (<i>p</i> < 0.05). The decision to be vaccinated is influenced by multiple factors (e.g., potential side-effects, sociocultural factors, impact of social media, pre-existing conditions and the wider context of the recent pandemic). <b>Conclusions:</b> Gardasil<sup>®</sup> appears to reduce the frequency of surgery and lessen disease severity in RRP patients, supporting the potential role of HPV vaccination as a therapeutic option for RRP. Moreover, it is crucial to overcome skepticism towards vaccinations to prevent the development of HPV-associated diseases in the first place. |
| format | Article |
| id | doaj-art-0b016f0f4d794e9e9241f64396f5d203 |
| institution | OA Journals |
| issn | 1999-4915 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj-art-0b016f0f4d794e9e9241f64396f5d2032025-08-20T01:50:10ZengMDPI AGViruses1999-49152025-02-0117332110.3390/v17030321Therapeutic Impact of Gardasil<sup>®</sup> in Recurrent Respiratory Papillomatosis: A Retrospective Study on RRP PatientsJennifer Sieg0Asita Fazel1Elgar Susanne Quabius2Astrid Dempfle3Susanne Wiegand4Markus Hoffmann5Department of Otorhinolaryngology, Head and Neck Surgery, Christian-Albrechts University Kiel, 24105 Kiel, GermanyDepartment of Otorhinolaryngology, Head and Neck Surgery, Christian-Albrechts University Kiel, 24105 Kiel, GermanyDepartment of Otorhinolaryngology, Head and Neck Surgery, Christian-Albrechts University Kiel, 24105 Kiel, GermanyInstitute of Medical Informatics and Statistics, Christian-Albrechts University Kiel, 24105 Kiel, GermanyDepartment of Otorhinolaryngology, Head and Neck Surgery, Christian-Albrechts University Kiel, 24105 Kiel, GermanyDepartment of Otorhinolaryngology, Head and Neck Surgery, Christian-Albrechts University Kiel, 24105 Kiel, Germany<b>Background:</b> Recurrent respiratory papillomatosis (RRP) is a rare, non-malignant disease caused by human papillomavirus (HPV) types 6 and 11. The condition primarily affects the larynx, potentially leading to life-threatening airway obstruction. It is more aggressive in younger patients, necessitating frequent surgical interventions. This study investigates the therapeutic potential of the prophylactic HPV vaccine Gardasil<sup>®</sup> in RRP patients, focusing on its impact on lesion size and the frequency of surgical interventions. Furthermore, a literature review was conducted to analyze the factors influencing the decision to vaccinate. <b>Methods:</b> A retrospective analysis was conducted on 63 RRP patients treated from 2008 to 2021. Disease burden was assessed using the Derkay score and the annual frequency of laser-surgical ablations. Comparisons were made between pre- and post-vaccination periods in vaccinated patients (n = 18), and between first and second halves of the disease’s course in unvaccinated patients (n = 14). <b>Results:</b> A reduction in the frequency of surgical interventions post-vaccination (<i>p</i> < 0.05) could be seen. The cumulated Derkay score per year decreased after second and third vaccination (<i>p</i> < 0.05). The decision to be vaccinated is influenced by multiple factors (e.g., potential side-effects, sociocultural factors, impact of social media, pre-existing conditions and the wider context of the recent pandemic). <b>Conclusions:</b> Gardasil<sup>®</sup> appears to reduce the frequency of surgery and lessen disease severity in RRP patients, supporting the potential role of HPV vaccination as a therapeutic option for RRP. Moreover, it is crucial to overcome skepticism towards vaccinations to prevent the development of HPV-associated diseases in the first place.https://www.mdpi.com/1999-4915/17/3/321HPVRRPvaccinationGardasil |
| spellingShingle | Jennifer Sieg Asita Fazel Elgar Susanne Quabius Astrid Dempfle Susanne Wiegand Markus Hoffmann Therapeutic Impact of Gardasil<sup>®</sup> in Recurrent Respiratory Papillomatosis: A Retrospective Study on RRP Patients Viruses HPV RRP vaccination Gardasil |
| title | Therapeutic Impact of Gardasil<sup>®</sup> in Recurrent Respiratory Papillomatosis: A Retrospective Study on RRP Patients |
| title_full | Therapeutic Impact of Gardasil<sup>®</sup> in Recurrent Respiratory Papillomatosis: A Retrospective Study on RRP Patients |
| title_fullStr | Therapeutic Impact of Gardasil<sup>®</sup> in Recurrent Respiratory Papillomatosis: A Retrospective Study on RRP Patients |
| title_full_unstemmed | Therapeutic Impact of Gardasil<sup>®</sup> in Recurrent Respiratory Papillomatosis: A Retrospective Study on RRP Patients |
| title_short | Therapeutic Impact of Gardasil<sup>®</sup> in Recurrent Respiratory Papillomatosis: A Retrospective Study on RRP Patients |
| title_sort | therapeutic impact of gardasil sup r sup in recurrent respiratory papillomatosis a retrospective study on rrp patients |
| topic | HPV RRP vaccination Gardasil |
| url | https://www.mdpi.com/1999-4915/17/3/321 |
| work_keys_str_mv | AT jennifersieg therapeuticimpactofgardasilsupsupinrecurrentrespiratorypapillomatosisaretrospectivestudyonrrppatients AT asitafazel therapeuticimpactofgardasilsupsupinrecurrentrespiratorypapillomatosisaretrospectivestudyonrrppatients AT elgarsusannequabius therapeuticimpactofgardasilsupsupinrecurrentrespiratorypapillomatosisaretrospectivestudyonrrppatients AT astriddempfle therapeuticimpactofgardasilsupsupinrecurrentrespiratorypapillomatosisaretrospectivestudyonrrppatients AT susannewiegand therapeuticimpactofgardasilsupsupinrecurrentrespiratorypapillomatosisaretrospectivestudyonrrppatients AT markushoffmann therapeuticimpactofgardasilsupsupinrecurrentrespiratorypapillomatosisaretrospectivestudyonrrppatients |